Clinical Trials Logo

Asthma clinical trials

View clinical trials related to Asthma.

Filter by:

NCT ID: NCT06313372 Not yet recruiting - Asthma Clinical Trials

Interpreting Respiratory Oscillometry in Adult Asthma and COPD: a Delphi Study

Start date: March 2024
Phase:
Study type: Observational

This is an international Delphi study to consolidate expert consensus on the use of respiratory oscillometry in the management of adult patients with asthma or chronic obstructive pulmonary disease (COPD). The primary objective of the Delphi study is to aid the interpretation of respiratory oscillometry in clinical practice amongst adult patients with asthma or COPD. This will be achieved by obtaining expert consensus on: - Which parameters are used in clinical practice for impulse oscillometry (IOS) and for forced oscillation technique (FOT) devices. - What cut-offs can be used for each parameter to guide clinical practice in the management of adult patients with asthma and COPD. This study is based on the Delphi methodology. The Delphi study will comprise of four rounds, one brainstorming round, to formulate the consensus survey, and three rounds to attempt to obtain consensus. In each round a questionnaire comprising of statements and questions regarding respiratory oscillometry will be sent to participants in the Delphi study electronically using SurveyLet, an online survey platform. Participants will respond anonymously to the survey questions, indicating their level of agreement or disagreement with each statement or question. Participants will be given 4 weeks to complete each round of the Delphi study. Questions and statements will be repeated in subsequent rounds until the predefined level of consensus is met or the maximum number of rounds is achieved (limited to a maximum of 3 rounds). Aggregated results for each statement or question, including distribution of results and consensus status, will be provided to participants after each round to facilitate informed decisions in subsequent rounds.

NCT ID: NCT06307665 Not yet recruiting - Asthma Clinical Trials

Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

ACADIA
Start date: March 27, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the budesonide/albuterol metered-dose inhaler (BDA MDI) with albuterol sulfate metered-dose inhaler (AS MDI) administered as needed on severe asthma exacerbations in adolescent participants aged 12 to < 18 years with a documented clinical diagnosis of asthma and at least one severe exacerbation in the prior year.

NCT ID: NCT06299592 Recruiting - Asthma Clinical Trials

Comparison of Microglial Activation in Severe Asthma and Healthy Controls

MAIA-SC
Start date: March 2024
Phase:
Study type: Observational

The goal of this clinical trial is to learn about how asthma influences brain function. The main questions it aims to answer are: - How airway inflammation in asthma affects the brain; and, - Whether airway inflammation in asthma is related to symptoms of depression and anxiety Over the course of 3 visits, participants will: - Complete questionnaires - Complete computer tasks - Undergo allergy skin test and breathing tests - Give two blood samples - Give a sputum sample - Complete brain imaging scans Researchers will compare results between participants with asthma, and participants who do not have asthma.

NCT ID: NCT06299306 Not yet recruiting - Asthma, Bronchial Clinical Trials

REACT - REAl Care for AsThma - A Disease Study to Identify Patients With Severe Uncontrolled Asthma

REACT-Asthma
Start date: March 15, 2024
Phase:
Study type: Observational

This is a multi-center, single-country, single-arm, prospective, disease study to collect real world data of patients with severe uncontrolled asthma in Germany.

NCT ID: NCT06291740 Not yet recruiting - Clinical trials for Emergency Department

Continuous Versus Intermittent Nebulization Therapy in Acute Asthma Exacerbation at Emergency Department

Start date: April 2024
Phase: N/A
Study type: Interventional

The goal of this clinical is to compare treatment outcomes between continuous nebulization and intermittent therapy in the management of acute exacerbation of asthma in the emergency department(ED). Participants will random assign to either continuous or intermittent nebulization. In the continuous group, patients receive budesonide, fenoterol, ipratropium bromide, and normal saline continuously for an hour. In the intermittent group, the same medications are administer every 20 minutes for an hour. Measurements include symptom severity, respiratory rate, oxygen saturation, and pulmonary function tests. Primary endpoints are ED stay length, hospital admission, and ED revisit within 48 hours post-discharge. Adverse events are documented.

NCT ID: NCT06290102 Not yet recruiting - Asthma Clinical Trials

Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old

Start date: April 2, 2024
Phase: Phase 1
Study type: Interventional

The primary objectives of this study are: - To determine the pharmacokinetic (PK) profile of fluticasone propionate (Fp) and albuterol sulfate (ABS), delivered in combination, from a single dose of TEV-56248 (Fp and ABS multidose dry powder inhaler with e-module [Fp/ABS eMDPI]) in participants with asthma - To compare the PK profiles of Fp for 2 different dose strengths of TEV-56248 to that of fluticasone propionate multidose dry powder inhaler (Fp MDPI) - To compare the PK profiles of ABS between the 2 different strengths of TEV-56248 The secondary objective is: • To evaluate the safety of a single dose of TEV-56248 and a single dose of Fp MDPI

NCT ID: NCT06288516 Recruiting - Clinical trials for Asthma; Eosinophilic

BenRalizumab Effect on Airway Remodeling in Severe asTHma

BREATH
Start date: March 1, 2024
Phase: Phase 4
Study type: Interventional

Response to biologic therapies in severe asthma is variable, with patients being either non-responders, responders or super-responders. There is currently no explanation for this broad variation in response. It is important to examine whether these patients have distinct characteristics that could help the treating physician in making the correct diagnosis in clinical practice. Aim of this clinical study is to evaluate the efficacy of benralizumab, a humanized an anti-interleukin 5 receptor α monoclonal antibody in patients with severe eosinophilic asthma and to evaluate airway remodeling before and after benralizumab treatment. Hypothesis Identification of pathological and clinical characteristics in patients with severe eosinophilic asthma after benralizumab treatment regarding the airway remodeling, inflammatory cells, and other biomarkers on a long-term basis. Research questions Is there any improvement in airway remodeling? Are there any biomarkers to predict response to benralizumab treatment in severe eosinophilic asthmatic patients?

NCT ID: NCT06286085 Not yet recruiting - Clinical trials for Ssess the Concordance of International Asthma Guidelines

A Comparison of Diagnostic Testing Modalities in the Assessment of Asthma

MODELS
Start date: February 26, 2024
Phase:
Study type: Observational

This study aims to assess the concordance of international asthma guidelines in the diagnosis of asthma and explore the presence of airways disease using additional non-guideline physiologic criteria, such as IOS, not included in the guidelines, but available in the Portsmouth lung function service.

NCT ID: NCT06286007 Recruiting - Asthma Clinical Trials

Prevalence and Impact of Pertussis and RSV on Asthma Severity and Control

PRIPASCO
Start date: December 21, 2023
Phase:
Study type: Observational [Patient Registry]

The main objective is to estimate the annual symptomatic incidence of Bordetella pertussis and RSV infections in patients aged 18 years and over with asthma, which will be identified by PCR, for Bordetella pertussis and by PCR for RSV performed at a specific timepoint from onset of symptoms for each symptomatic Acute Respiratory Infection (ARI). A multicentre prospective cohort study will be undertaken in Spain. Thirty-five centres from different autonomous communities in Spain will participate in the study. Participants will be asked to report to the investigator if they experience an asthma exacerbation or symptoms of acute respiratory infection with 2 years follow up

NCT ID: NCT06283290 Not yet recruiting - Severe Asthma Clinical Trials

PROPE Severe Asthma Study in Egypt

Start date: March 1, 2024
Phase:
Study type: Observational

Asthma is a syndrome characterized by airway inflammation, reversible airway obstruction, and airway hyper-responsiveness. Patients present clinically with recurrent wheezing, shortness of breath, cough, and chest tightness. Asthma is a leading cause of morbidity with a global prevalence of approximately 300 million; it is estimated that the number of people with asthma may increase to 400 to 450 million people worldwide by 2025. Severe asthma is not considered a single disease; instead, it is divided into several phenotypes, owing to the variety of inflammatory, clinical, and functional characteristics that it can present with. One of the proposed and most studied phenotypes is severe eosinophilic asthma. Patients with severe asthma that is accompanied by a high concentration of eosinophils require greater healthcare resource use, greater disease management costs, and a much more impaired QoL than those who do not present with raised eosinophilia. While the number of targeted treatments for asthma management has been growing in recent years, the heterogeneity of clinical presentations, treatment responses, and inflammatory processes involved represent an added challenge for health care professionals. Thus, severe asthma management is a complex endeavor, and a thorough and up-to-date understanding of the pathophysiologic characteristics of the patient population promotes effective therapeutic decision-making. This cross-sectional, multicenter study aims to determine the prevalence of oral corticosteroid (OCS) use among severe asthma patients who attend to different sites specialized in the management of severe asthma across Egypt. In addition, the prevalence of eosinophilic phenotype of blood eosinophil count ≥ 150 cells/mm3, prevalence of atopic phenotype, and asthma control will also be studied.